1 / 23

VWOG richtlijn vulvacarcinoom Herfst symposiumVVOG Kinepolis Brugge

VWOG richtlijn vulvacarcinoom Herfst symposiumVVOG Kinepolis Brugge. Frédéric Amant Namens VWOG bestuur. Tissue is the issue!. Vulvar intraepithelial disease Squamous cell carcinoma (90%) Verrucoid cancer Basal cell ca Adenocarcinoma Paget’s disease

tiffanie
Télécharger la présentation

VWOG richtlijn vulvacarcinoom Herfst symposiumVVOG Kinepolis Brugge

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VWOG richtlijn vulvacarcinoomHerfst symposiumVVOGKinepolis Brugge Frédéric Amant Namens VWOG bestuur

  2. Tissue is the issue! • Vulvar intraepithelial disease • Squamous cell carcinoma (90%) • Verrucoid cancer • Basal cell ca • Adenocarcinoma • Paget’s disease • Bartholin gland carcinoma (40% squamous) • Melanoma • Malignant mesenchymal tumors • Metastatic

  3. VIN III: Triad of three P’s: parakeratosis, pigment, papulae

  4. Vulvar Intraepithelial Neoplasia • Low grade VIN: subclinical HPV infection • High grade VIN: - moderate to severe dysplasia - undisputed malignant potential - 30-50% co-existence with vulvar ca - S/ no, pruritus, burning, pain, dysuria - R/ surgical excision (laser, cold knife)

  5. Diagnostic work-out • KO: operability & groin • Chest X-ray • CT abdomen, inclusive groin • SCC in blood • On indication: recto- en cystoscopy, CT-thorax

  6. Treatment modalities in vulvar cancer • Stage Ia(< 1mm depth of invasion  0% + inguin LN partial vulvectomy • Stage Ib-III (partial) vulvectomy inguinofemoral lymphadenectomy/ sentinel node procedure • Stage IVa exenteration/neoadjuvant CT/45-65Gy • Stage IVb palliation

  7. Total vulvectomy

  8. The price of less radical surgery • Surgical tumor-free margin • > 8 mm: no vulvar recurrence, n=91 • < 8 mm: 21/44 (48%) vulvar recurrence • Heaps et al., Gynecol Oncol 1990;38:309-14 • Surgical tumor-free margin • >8 mm: no vulvar recurrence, n=39 • < 8 mm: 9/40 (22.5%) vulvar recurrence • de Hullu et al., Cancer 2002;95:2331-8

  9. What is an adequate resection margin?Ibrahim et al., IGCS 2006, Santa Monica Abstract 36 • 15 consecutive patients • At least 10 mm clear margin macroscopically • Reduction of clear margin • 15% post resection • 15% tissue fixation • 15% microscopically • Totalling 45% reduction • 1 cm is insufficient as macroscopic margin

  10. Impact of partial (< 1.5 cm) urethral resectionde mooij et al., Int J Gynecol Cancer 2007;17:294-7

  11. M Pectineus m adductor longus M abdominis, sheet femoral artery and vein M sartorius

  12. Apex of the femoral triangle Femoral vein Sartorius muscle Femoral artery

  13. Ipsilateral superficial inguinal lymphadenectomyStehman et al., Obstet Gynecol 1992;79:490-7 • Prospective evaluation • N = 155 • 7.3% inguinal recurrence rate • Historical control: 0% inguinal recurrence rate Recurrence rate varies from 0-8.6%(Berman 1989; Stehman 1992; Burke 1995; Gordinier 2003; Kirby 2005) Number of recurrences attributable to decision to leave the femoral nodes

  14. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer: morbidityVan der Zee et al., JCO 2008;26:884-9

  15. Fig 2. (A) Cumulative proportion of groin recurrences in patients with unifocal vulvar cancer < 4 cm and negative sentinel node (dark blue line); 95% CIs are also given (light blue lines) 6/259 (2.3%) 97% 3y survival Van der Zee, A. G.J. et al. J Clin Oncol; 26:884-889 2008

  16. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer: quality control at each stepVan der Zee et al., JCO 2008;26:884-9 • Injection of radioactive tracer • Interpretation of lymphoscintigram • Surgeon: 10 patients/year/surgeon • Pathology: experience with ultrastaging

  17. Patient met T1 of T2 (<4cm) vulvair carcinoom zonder verdachte liezen Metastase: volledige lymphadenectomie Radiologie (Ct of MR) om verdachte klieren te identificeren; zo verdacht echografie + fijne naald aspiratie Geen metastase Geen sentinel lymfeklier: technisch falen? Logistiek probleem? • Sentinel lymfeklier procedure met gecombineerde techniek (preoperatief lymphoscintigraphy met 99m Technetium gelabeld nanocolloid en patent blauw). • Verwijderde SLNs voor vriescoupe. • Intraoperatieve palpatie om vaste lymfeklieren te voelen. • Patholoog informeert gynaecoloog over aantal SLN’s. • Brede locale excisie. • In liezen met een positieve SLN bij vriescoupe een volledige inguinofemorale lymphadenectomie. • Bij problemen ter identificatie van de SLNs eerst verwijderen primaire tumor om radioactiviteit te verminderen en nadien de SLN’s • Definitieve pathologie: (micro) metastase in SLN(‘s): secundaire volledige lymphadenectomie. Ja: herhaal procedure Nee: volledige inguinofemorale lymphadenectomie Zo meer dan 1 intranodale metastase of extranodale groei: postoperatieve radiotherapie FOLLOW-UP Flow chart sentinelklierprocedurede Hullu et al., Gynecol Oncol 2004;94:10-5

  18. Vulvar > 4 cm Ø < 8 mm resection margin Significant lymfatic permeation Inguinofemoral Macrosc + nodes  2 microscopic nodes Indications for postop radiochemotherapy of the groin and ipsilateral hemipelvis

More Related